Sutro Biopharma, Inc. (S09.F)
| Previous Close | 6.55 |
| Open | 6.55 |
| Bid | 6.50 x 0 |
| Ask | 6.75 x 0 |
| Day's Range | 6.55 - 6.55 |
| 52 Week Range | 3.20 - 9.25 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 399.253M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptom
- GlobeNewswire
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. The presentation will be accessible through the News & Ev
- GlobeNewswire
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC
